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Abstract	
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb). TB 
mainly affects lungs of patients but other parts of the body can also be affected. It kills 
approximately 2 million people annually. HIV/AIDS and drug resistance make TB difficult to 
control. Mtb CarD protein forms a physiological complex with Ribonucleic Acid Polymerase 
(RNAP). This complex causes Mtb to undergo dormancy rendering it difficult to control using 
current antibiotics. CarD and a size-reduced subunit β1 (denoted β1m for “minimized”) of 
Thermus thermophilus RNAP, in which the central domain has been replaced by a Gly-Gly 
linker, were produced and purified using affinity nickel nitrilotriaceticacid and glutathione-S-
transferase (GST) affinity chromatography techniques respectively. CarD N terminal domain 
(CarDN) was generated from CarD by inserting a stop codon by site directed mutagenesis. 
CarD was stabilised by adding 5 % (v/v) glycerol to PBS pH 7.4 ensuring protein stability of 
up to 67 days rather than 2 days without glycerol. CarDN was stable in PBS pH 7.4 without 
addition of glycerol. This suggests that the CarD C terminal domain may be responsible for 
CarD instability. To further purify the proteins both anion exchange and gel permeation 
chromatography techniques were used. CarD and CarDN degrade immediately after anion 
exchange potentially because of the high ion concentration which partially unfolds the protein 
making it prone to proteolytic cleavage. GST-pull down assays were used to demonstrate 
complex formation between RNAP β1m and both CarD and CarDN confirming that complex 
formation is dependent on the N-terminal domain of CarD. 
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1.0 Introduction 
1.1 Brief History and Transmission of Tuberculosis 
1.1.1 Definition 
Tuberculosis (TB) is a contagious human disease. In 1882 Robert Koch proved 
Mycobacterium tuberculosis (Mtb) to be the etiological agent of TB (Mcdonough et al. 1993). 
The bacterium is Gram positive, rod shaped and ~2-4 µm long. Mtb is classified as “acid fast” 
because its cell wall resists staining by acids in the laboratory. The underlying reason for this 
phenomenon is the mycolic acid constituents of their cell walls which only poorly absorb acid 
fast stains like carbol fuschin. TB primarily affects the lungs of patients (pulmonary TB) 
though other parts of the body may also be affected (extra-pulmonary TB) (Bordbar et al. 
2010; Deb et al. 2009). 
1.1.2 Epidemiology 
TB is one of the most lethal infectious diseases globally especially when occurring in 
combination with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome 
(HIV/AIDS) and malaria killing an estimated 2 million people annually (Ordway et al. 2007; 
Ordway et al. 2010). A third of the world’s population harbours Mtb bacilli though mostly in a 
latent or dormant form. About one in twenty of these will develop active disease during their 
lifetime (Grosset 2003; Clark-Curtiss & Haydel 2003). Overall men are more susceptible to 
TB than women (Anon 2012), with the exception of women in reproductive age who develop 
TB more often than their male counterparts (Ordway et al. 2010). 
TB, as it is known today, has afflicted humans throughout the ages. Previously it was more 
commonly referred to as “consumption”, due to the patient’s body being “consumed” by the 
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disease, the “white plague”, due to the patients’ pale skin, or “phthisis pulmonaries”, or 
“Pott’s disease”. Mtb has been demonstrated in human remains from ancient Egypt, India and 
China 15000 to 20000 years ago (Daniel 2006). In Egypt, archaeologists have detected spinal 
TB in mummies (Barnes 2000).  
Rapid urbanization in industrializing countries accompanied by suboptimal living conditions 
allowed TB to spread rapidly in the 18th century (Daniel 2006) increasing lethality 
(Mcdonough et al. 1993). Growing knowledge of the disease (Barnes 2000; Daniel 2006) and 
improving sanitation caused mortality rates to drop significantly in the late 19th century. The 
discovery of highly effective anti-tuberculosis drugs in the mid-20th century nearly eradicated 
Mtb (Clark-Curtiss & Haydel 2003; Bordbar et al. 2010), only for TB to re-emerge decades 
later in combination with HIV/AIDS. TB in particular appears to benefit from the HIV-
induced suppression of the human immune system, making TB the leading cause of death in 
HIV/AIDS patients (Daniel 2006). Growing antibiotic resistance of Mtb together with HIV 
increased TB incidences in developed countries in the late 1900’s (Barnes 2000). Developing 
countries, and especially sub-Saharan Africa, however, bore the brunt of this growing 
epidemic due to factors such as poor sanitation, malnutrition, lack of drugs and the advent of 
HIV/AIDS (Mcdonough et al. 1993; Schluger & Rom 1998; Barnes 2000; Anon 2012). 
1.1.3 Transmission of Mtb 
Mtb is transmitted by aerosols from active TB patients to other humans through sneezing, 
speaking and coughing (Mcdonough et al. 1993; Betts et al. 2002; Fontán et al. 2008). The 
half-life of Mtb within drying droplets is estimated at 6 h (Grosset 2003) while Mtb-containing 
particles may remain suspended in air for several hours aiding their dispersal (Ordway et al. 
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2007; Grosset 2003). Presumably a single such particle can suffice to elicit a new infection 
(Betts et al. 2002; Grosset 2003). 
Droplets larger than 1-2 µm in diameter are normally eliminated by physical barriers such as 
the nasopharynx and upper respiratory tract (Schluger & Rom 1998). On the other hand, 
secretion of antimicrobial peptides with a broad killing spectrum makes the respiratory 
bronchial epithelium resistant to Mtb (Schluger & Rom 1998; Davis & Ramakrishnan 2009). 
After arriving in lung alveoli Mtb faces three potential fates: Either bacteria are eliminated 
entirely by the host response, bacteria replicate and initiate clinical disease (pulmonary TB), 
or bacteria become dormant (latent TB) (Primm et al. 2000). This latent infection can develop 
into fully blown active TB when dormant bacteria undergo reactivation (Kapoor et al. 2013).  
1.2 Immune Response to Mtb 
The innate immune system is the first line of defence against TB, clearing all invading Mtb in 
~50% of exposed individuals (Flynn & Ernst 2000; Schluger & Rom 1998) without 
involvement of the adaptive branch of the immune system (Welin 2011; Flynn & Ernst 2000; 
Serbina et al. 2001). Clearly the associated margin of error is rather large due to ethical 
implications of any potential experiments (Ordway et al. 2007; Anon 2012; Serbina et al. 
2001). Boosting the innate immune system through immunomodulatory drugs is thus an 
attractive strategy to limit Mtb infection. 
Macrophages are the first cell-type of the innate immune system to combat Mtb (Davis & 
Ramakrishnan 2009) – although Mtb can under suitable circumstances replicate in resting 
macrophages. Protective immunity is mediated by T lymphocytes that activate anti-
mycobacterial activities of macrophages killing the pathogen. However, despite an active 
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immune response, Mtb is able to persist in a dormant stage. Latent infection is thus the 
outcome of a continual immune response (Wolf et al. 2008).  
When the immune system is suppressed, Mtb is no longer suppressed and active disease 
develops (Kumar & Sanyal 1998; Marino & Kirschner 2004). In fact, Mtb makes use of the 
innate immune system for its pathogenesis inter alia by using innate immune receptors to 
adhere to macrophages such as mannose, Toll-like receptors, pathogen recognition receptors, 
complement and scavenger receptors (Schluger & Rom 1998; Davis & Ramakrishnan 2009). 
1.2.1 Phagocytosis 
Mtb passively access lung alveoli by inhalation. Their lipopolisacharides and peptidoglycans 
activate naïve alveolar macrophages through surface receptors (Davis & Ramakrishnan 2009; 
Fontán et al. 2008; Ordway et al. 2010) increasing their rate of ingesting and killing microbes. 
Macrophages increase the levels of major histocompatibility complex II (Davis & 
Ramakrishnan 2009; Fontán et al. 2008) presenting antigen to T-helper cells and initiating the 
collaboration between innate and adaptive immunity (Wolf et al. 2008). Other immune cells 
are recruited to the site of infection around the macrophages forming a caseous material called 
granuloma (Kapoor et al. 2013). 
Upon phagocytosis, bacteria-containing phagosomes fuse with lysosomes containing 
hydrolytic enzymes such as defensins and lysozyme (Fontán et al. 2008) as well as reactive 
oxygen generating systems such as nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase (Davis & Ramakrishnan 2009) to digest and kill phagocytized bacteria (Wolf et al. 
2008). The membrane-integral NADPH oxidase produces superoxide by transferring electrons 
from intracellular NADPH and coupling these to molecular oxygen to produce the reactive 
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radical superoxide anion inside the phagosome (Flynn & Ernst 2000; Marino & Kirschner 
2004; Keertan et al. 2010; Schluger & Rom 1998).  
Evasion mechanisms of Mtb have not been fully characterized. Mycobacteria do produce 
ammonia to inhibit phagosome-lysozyme fusion and alkalinizing the lysosomal contents 
thereby reducing the potency of this fusion complex (Schluger & Rom 1998). While the host 
immune response kills most bacteria, some do survive but become dormant for extended 
periods potentially reactivating much later to cause active TB (Fontán et al. 2008; Schluger & 
Rom 1998). 
1.3 Treatment 
 
Common antibiotics used to treat Mtb are isoniazid and rifampicin, which together with 
pyrazinamide form the first line of treatment regimen (Wehrli 2013; Ordway et al. 2010). 
These antibiotics target actively growing bacteria (Stallings & Glickman 2011; Srivastava et 
al. 2013). Pyrazinamide, which reduces treatment from nine to six months, targets semi-
dormant and old non growing bacilli, exerting its function at acidic pH (Zhang et al. 2003). 
Pyrazinamide action is slow and it kills less than 76% of the bacterial population (Zhang et al. 
2003; Ordway et al. 2010) meaning that it cannot overcome latency entirely. 
Initially, first line of protection was 90% effective (Jain et al. 2008). However this relief was 
short lived as Mtb developed resistance against them. This prompted the introduction of 
second line of protection (Table 1). Second line of protection drugs proved to have more side 
effects than their predecessors in recipients (Kapoor et al. 2013). It is therefore imperative that 
new therapeutic intervention which is expeditious and effective be identified. 
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Table 1: First and Second-line Anti-TB Drugs (Jain et al. 2008) 
First-line drugs Second-line drugs 
Para-aminosalicylic acid Viomycin 
Isoniazid Fluoroquinolones 
Rifampicin Ofloxacin 
Rifapenline Cipromycin 
Pyrazinamide Aminoglycosides 
Streptomycin Kanamycin 
Ethambutol Amikacin 
 Ethiolnamide 
 D-Cycloserine 
 
1.4 Stringent Response 
 
The stringent response is a bacterial survival mechanism (Fontán et al. 2008; Magnusson et al. 
2005; Potrykus & Cashel 2008) geared towards amino acid starvation, DNA damage, nutrient 
starvation and phosphate deprivation (Stallings & Glickman 2011; Stallings et al. 2003). 
Bacteria synthesize the alarmones guanosine tetraphosphate (ppGpp) (Barker et al. 2001) and 
guanosine pentaphosphate (pppGpp) (Potrykus & Cashel 2008). The enzyme RelA or RelMtb 
(Kapoor et al. 2013) controls both synthesis and degradation of these signalling molecules 
(Primm et al. 2000) by triggering the stalled ribosome with an uncharged tRNA in the 
acceptor site to produce ppGpp (Raskin et al. 2007; Brockmann-gretza 2006; Betts et al. 
2002). With the aid of the transcription factor DksA, ppGpp directly binds to the RNA 
polymerase secondary channel near the catalytic centre reducing rRNA synthesis (Ferullo & 
Lovett 2008). Another enzyme, SpoT, hydrolyses ppGpp. 
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1.4.1 Small Molecule Effectors and Initiating Nucleoside Triphosphate 
Promoters regulate initiation of transcription to produce rRNA (Nickels & Hochschild 2004) 
by initiating nucleoside triphosphate (iNTP) and ppGpp on the open complex (Paul et al. 
2004) in a concentration dependent manner. Increasing iNTP concentrations stimulate rRNA 
transcription by transiently stabilizing the open complex (Paul et al. 2004). ppGpp, by 
contrast, inhibits transcription by binding to the secondary channel near the RNAP active site 
(Rutherford et al. 2007) and potentially base pairing with exposed cytosines in the non-
template strand to decrease the lifetime of the open complex (Paul et al. 2004; Brockmann-
gretza 2006). Independent of its orientation, ppGpp coordinates Mg2+at either its 3’ or 5’ end 
(Vrentas et al. 2008) physically linking it to the transcription regulator DksA (Nickels & 
Hochschild 2004; Rutherford et al. 2007; Barker et al. 2001). 
1.4.2 DksA 
The 151 amino acid transcription factor DksA critically regulates rRNA production (Nickels 
& Hochschild 2004) by binding to the secondary channel of RNAP (Gaal 1997). A crystal 
structure reveals that the DksA coil-coiled domain extends deep into the secondary channel 
similar to other Gre transcription factors (Nickels & Hochschild 2004; Paul et al. 2004). Two 
aspartate residues at the tip of this domain coordinate Mg2+, which is in turn coordinated by 
ppGpp binding it to the transcription complex (Nickels & Hochschild 2004; Paul et al. 2004; 
Potrykus & Cashel 2008). Regulation of rRNA production by either ppGpp or iNTP requires a 
short-lived initiation complex. DksA shortens the lifetime of the open complex of 
transcription initiation sensitizing it to small molecule effectors (Magnusson et al. 2005; 
Rutherford et al. 2007; Brockmann-gretza 2006). 
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1.5 CarD 
 
Protein-protein interactions of transcription regulatory proteins are important in regulating 
transcription (Gaal 1997). One such transcription regulator, CarD, is found in many bacteria 
such as Myxococcus xanthus, Borrelia burgdorferi and Thermus thermophilus (Galbis-martı et 
al. 2004; García-heras et al. 2013) but not in eukaryotes and archaea (Garcı et al. 2010). 
Borrelia burgdorferi codes for LtpA, a CarD homolog, whereas M. xanthus produces a CarD 
ortholog involved in fruiting body production (Yang et al. 2008). All sequenced mycobacterial 
genomes code for CarD underscoring its physiological relevance (Weiss et al. 2012) with 
98.1 % and 95.7 % sequence identity between M. smegmatis CarD and those of Mtb and M. 
leprae respectively. Functionally, CarD resembles DksA of E. coli (Garcı et al. 2010). 
1.5.1 Molecular characterization of Mtb CarD 
CarD of Mtb is 162 amino acids in length and consists of an N-terminal domain (CarDN) of 64 
amino acids and a C-terminal domain of 98 residues (Stallings et al. 2009). The N-terminal 
domain shares 60 % sequence identity with RNAP interacting domain (RID) of transcription 
repair coupling factor (TRCF) of E. coli (Westblade et al. 2010) and interacts with the β1-
subunit of RNAP (Stallings & Glickman 2011) analogous to TRCF-RID (Westblade et al. 
2010; Srivastava et al. 2013). The C-terminal domain, thought to bind DNA (Garcı et al. 2010; 
García-heras et al. 2013), is essential for CarD stability (Stallings & Glickman 2011; 
Westblade et al. 2010). 
1.5.2 Complex of CarD with RNAP β1-subunit 
Transcription regulatory factors control RNAP transcription of DNA to mRNA (Gaal 1997). 
Two-hybrid assay and immunoprecipitation experiments indicate that Mtb CarD binds to the 
N-terminal domain of the RNAP β1-subunit (RNAP β1) by its RID domain (Stallings et al. 
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Figure 1: Biophysical Effects of Mtb CarD Binding RNAP (Weiss et al. 2012) 
2009). Although TRCF and CarD bind similar sites in RNAP, their functions are distinct such 
that CarD- and TRCF-RID cannot functionally replace each other (Stallings & Glickman 
2011). 
CarD binding to RNAP β1 subunit elicits a number of downstream effects (Figure 1) that 
limit transcription to proteins essential for Mtb persistence. rRNA production is down 
regulated to match the declining need of proteins to allow the cell to survive stressful 
conditions such as starvation (Stallings & Glickman 2011). Mtb correspondingly enters a state 
of dormancy. Altering the CarD/RNAP β interaction could terminate dormancy, sensitizing 
Mtb to physiological stresses (Priya & Megha 2012). CarD also appears to be involved in 
limiting conflict between transcription and replication (Srivastava et al. 2013).  
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1.5.3 CarD in Mtb Persistence 
Mtb persistence mechanisms include the repair of double stranded DNA breaks (DSB) without 
DNA template (Stallings and Glickman, 2011). CarD was implicated in DNA DSB repair, 
though its precise role remains to be elucidated. Other functions of CarD in Mtb persistence 
include the stringent response control mechanism, responses to environmental stresses and 
viability of Mtb (Srivastava et al. 2013). CarD is critical for growth as its removal results in 
retarded growth (Stallings & Glickman 2011; Stallings & Michael 2010). 
1.5.4 CarD is Essential for Mtb Viability 
Deletion of carD in both Mtb and M. smegmatis were unsuccessful (Stallings et al. 2009). Its 
conditional depletion similarly confirm that CarD is essential for Mtb viability as well as for 
homeostasis and growth (Priya & Megha 2012). Defects in CarD correlate with impaired 
growth of Mtb and sensitivity to genotoxins and hydrogen peroxide (Stallings & Michael 
2010). 
1.5.5 CarD is Essential for Survival of Nutrient Limitation and Oxidative Stress 
Mtb survival in granuloma despite nutrient deprivation implies specialized cellular processes 
for their persistence (Kapoor et al. 2013; Davis & Ramakrishnan 2009; Ordway et al. 2010). 
This includes CarD up-regulation during nutrient deprivation and under oxidative stress 
(Stallings et al. 2009). Mtb strains unable to produce CarD are killed by oxidative agents such 
as ciprofloxacin, bleomycin and hydrogen peroxide, while strains producing CarD are largely 
unaffected (Srivastava et al. 2013).  
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1.5.6 CarD is Required for the Stringent Response 
Induction of CarD results in reduced RNA levels in Mycobacteria (Stallings et al. 2009). In 
most bacteria including E. coli, stable RNA synthesis is accomplished by the stringent 
response (Magnusson et al. 2005; Vrentas et al. 2008; Barker et al. 2001) during which ppGpp 
down regulates synthesis of RNAs related to environmental stress (Primm et al. 2000; 
Magnusson et al. 2005; Vrentas et al. 2008). E. coli cells lacking proteins such as ppGpp-
producing RelA are unable to grow on amino acid deficient media (Weiss et al. 2012). 
The stringent response in Mtb works differently (Stallings et al. 2009) and involves CarD 
(Stallings & Glickman 2011, Stallings & Michael 2010). Thus CarD alongside ppGpp-
producing RelA is essential for stringent response. 
1.6 Comparing CarD to TRCF and DksA 
 
DksA of E. coli shares some features of CarD (Weiss et al. 2012; Stallings et al. 2010) so 
much so that CarD can partly substitute for DksA in E. coli (Stallings & Glickman 2011). 
DksA and CarD binding sites on RNAP do, however, not overlap (Priya & Megha 2012) 
implying that CarD and DksA achieve similar functions through different protein-protein 
interactions. DksA, furthermore, is non-essential in E. coli (Paul et al. 2004) and its effect is 
evident only under high nutrient conditions – the opposite of CarD (Stallings et al. 2009). 
Both TRCF-RID and CarD bind to the β-subunit of RNAP (Srivastava et al. 2013; Westblade 
et al. 2010) and they share a sequence identity of 60% (Westblade et al. 2010). Nevertheless, 
CarD cannot substitute for DksA in E. coli and TRCF-RID does not have the same effect as 
CarD in Mtb. 
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1.7 Problem Identification 
Mtb has developed resistance to many standard antibiotics making TB one of the deadliest 
human diseases. To survive stress conditions, Mtb enters a dormant state limiting the efficacy 
of antibiotics. The physiological complex of CarD with RNAP, which initiates the dormant 
state by down regulating transcription remains to be structurally characterized. Such a 
structure could help to unravel the disparate roles of CarD in Mtb persistence and dormancy 
and aid the development of drugs to prevent this critical interaction as a first step in 
overcoming persistence and dormancy. Ideally this would involve a structural and biophysical 
characterization of CarD on its own as well as in complex with RNAP. 
1.8 Research Aim and Objectives 
1.8.1 Aim 
The overall aim of this project is to elucidate the physiological CarD/RNAP complex of Mtb. 
1.8.2 Objectives 
The project focused on the following objectives. 
1) Produce and purify full-length CarD. 
2) Stabilize CarD. 
3) Generate a clone for CarDN. Produce and purify CarDN. 
4) Produce and purify Mtb RNAP β1m. Clone, produce and purify Taq RNAP β1m. 
5) Test for binding between CarD and both Taq and Mtb RNAP β1m.  
6) Purify CarD/Mtb RNAP β1m  and CarDN/Taq RNAP β1m. 
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2.0 Materials and Methods 
2.1 Chemicals and Reagents 
General chemicals and reagents were purchased from Sigma or Merck except where otherwise 
specified. 
2.2 Primers 
Polymerase chain reaction (PCR) and site directed mutagenesis (SDM) primers were designed 
manually. PCR primers conformed to the following rules:  
1) Length: 15 to 30 nucleotides. 
2) Melting temperature, Tm = 4 (G+C) + 2 (A+T), where G, C, A, T are the number of 
corresponding nucleotides in the primer. 
3) Tm of forward and reverse primers should differ by ≤ 5 °C.  
SDM primers, by contrast, were 25 to 45 nucleotides long to achieve Tm ≥ 78 °C. Altered 
nucleotides were positioned near the middle of the primers. 
Forward and reverse primers for the cloning of Mtb RNAP β1 were designed using the 
restriction-free software, http://www.rf-cloning.org/. DNA sequences for the rnaP β1 gene 
and pGEX-6P-2 vector were provided. The software proposed primers of 51 nucleotides 
combining sequences respectively complementary to the rnaP β1 and to pGEX-6P-2. Primers 
were purchased from Inqaba Biotech (Table 2). The mutations are underlined and shown in 
bold. 
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Table 2: List of Primers 
Primer  
Length 
(bases)  
Sequence 
Mtb-RNAP β1 forward 28 5’-ATGGTCGGATCCGGACTCCTTGACGTC -3’ 
Mtb-RNAP β1 reverse 34 
5’-ATCTGACGCGGCCGCCTAGAATTGGCTCA
GCTGG-3’ 
Mtb-RNAP β1-RF forward 40 
5’-GTTCTGTTCCAGGGGCCCCTGGGGACTCCT
TGACGTCCAG-3’ 
Mtb-RNAP β1-RF reverse 42 
5’-GTCAGTCAGTCACGATGCGGCCCTAGAAT
TGGCTCAGCTGGC-3’ 
Mtb-RNAP β1m-SDM forward 34 
5’-TGGTGGTCAGCCAGGGAGGTCGTACGGTC
GGCGA-3’ 
Mtb-RNAP β1m-SDM reverse 34 
5’-TCGCCGACCGTACGACCTCCCTGGCTGAC
CACCA-3’ 
Mtb-CarDN forward 51 
5’-GGTGTTCGTGATGTTGTTGGTCAATAAGAA
GGTCTGGATAAAGTTTTTCAG-3’ 
Mtb-CarDN terminus reverse  51 
5’-CTGAAAAACTTTATCCAGACCTTCTTATTG
ACCAACAACATCACGAACACC-3’ 
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2.3 Plasmids 
Names, features and suppliers of plasmids used in the study are listed in Table 3. 
Table 3: Utilized Plasmids 
Plasmid 
Size 
(Kb) 
Selection Tag Position Cleavage site Source 
pGEX-6P-1 4.9 AmpR GST N-terminal PreScission protease* GE Healthcare 
pGEX-6P-2 4.9 AmpR GST N-terminal PreScission Protease* GE Healthcare 
pET-28a 5.4 KanR His6 N-terminal Thrombin Novagen 
PreScission protease is a human rhinovirus C3 protease. 
2.3 Recombinant Plasmids 
Recombinant plasmids used in this work are summarized in Table 4 with restriction sites on 
either side of the gene of interest. 
Table 4: List of Recombinant Plasmids Used in the Study 
 
Plasmid Restriction sites Source 
pGEX-6P-1-CarD BamHI, NotI Previous work by Lilia Polle 
pGEX-6P-1-CarDN BamHI, NotI Current work
pGEX-6P-2_Mtb-RNAP  BamHI, NotI Current work
pET28a_Taq-RNAP β1m NdeI, HindIII Rockefeller University, New York, USA  
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2.4 Expression Cells 
A number of  competent expression cells were used (Table 5). 
Table5: Competent Expression Cells Used in the Study 
E. coli strains Source
Rosetta 2  Novagen
BL21 (DE3) Stratagene
BL 21+ Stratagene 
DH5α Stratagene
Gene Hogs Stratagene 
 
2.5 Preparation of Solutions, Media and Buffers 
All buffers, media, and sterile materials were autoclaved for 20 min at 121 °C. Heat-sensitive 
components were filter-sterilized with 0.2 µM filters and degassed. 
2.5.1 Lysogeny Broth and Agar Plates 
Lysogeny broth (LB) medium was prepared by dissolving 10 g tryptone, 5 g yeast extract 
powder and 5 g NaCl in 500 mL deionized water before making up to 1 L and autoclaving. 
For LB agar additionally 15 g of bacteriological agar was added. The medium was allowed to 
cool to around 40 °C before adding appropriate antibiotics. Petri dishes were filled with ~25 
mL of liquid agar in the laminar flow cabinet, spread by gentle swirling and allowed to set for 
1 h. They were stored at 4 C for later use. 
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2.5.2 Buffers and Solutions 
Table 6: Buffers and Solutions 
Buffers/Solutions Composition 
Lysis buffer 
 
1 x PBS pH 7.0, Complete EDTA-free Protease Inhibitor 
Cocktail Tablet and 10 µg/mL DNaseI 
PreScission protease cleavage buffer 
10 mM Tris/HCl pH 7.0, 150 mM NaCl 
GST elution buffer 1 x PBS pH 7.4
Ni-NTA equilibration buffer 1 x PBS pH 7.4 
Ni-NTA wash buffer 
1 x PBS pH 7.4, 10 mM imidazole 
Ni-NTA elution buffer
1 x PBS pH 7.4, 250 mM imidazole 
TAE buffer 40 mM Tris-HCl pH 7.5, 20 mM sodium acetate, 
1 mM EDTA, adjusted to pH 8.2 with acetic acid 
Anion exchange buffer A  
20 mM Tris-HCl pH 7.0, 25 mM NaCl 
Anion exchange buffer B  
20 mM Tris-HCl pH 7.0, 1 M NaCl 
Gel filtration buffer  5 % (v/v) glycerol, 1 x PBS pH 7.4
10 x DNA loading buffer 70 % (w/v) sucrose, 0.25 % (w/v) bromophenol blue, 0.1 M 
EDTA 
SDS-PAGE running buffer 25 mM Tris-HCl, 192 mM glycine, 0.1 % (w/v) SDS 
SDS-PAGE sample buffer (8 x) 16 mL 10 % SDS, 4 mL glycerol, 2.2 mL 1.5 mM Tris/HCl 
pH 6.8, 800μL β-mercaptoethanol, 1 spatula tip 
bromophenol blue 
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SDS-PAGE separating gel (15 %) 15 mL acrylamide/bisacrylamide 30 %/0.8 % (w/v), 7.6 mL 
1.5 M Tris-HCl pH 6.8, 300 μL 10 % (w/v) SDS, 10 mL 
ddH2O, 40 μL TEMED, 100 μL 25 % (w/v) APS 
SDS-PAGE stacking gel (5 %) 1.5 mL acrylamide/bisacrylamide 30 % (w/v)/0.8 % (w/v), 
2.5 mL 0.5 M Tris-HCl, pH 6.8, 5.9 mL ddH2O, 15 μL 
TEMED, 25 μL 25 % (w/v) APS 
SDS-PAGE Staining solution 0.25 % (w/v) Coomassie Brilliant Blue R-250, 30 % (v/v) 
ethanol, 10 % (v/v) acetic acid 
SDS-PAGE destaining solution 40 % (v/v) ethanol, 10 % (v/v) acetic acid 
 
2.5.3 Liquid Culture 
Bacteria were grown in liquid medium using baffled Erlenmeyer flasks for aeration. Flasks 
with inoculated liquid media and appropriate antibiotics (0.1 µg/mL) were incubated at 37 °C 
and a rotation speed of 160 rpm overnight. Liquid bacterial cultures were prepared for pre-
cultures, protein production, DNA preparation and glycerol stocks. 
2.6 Molecular Biology 
2.6.1 Polymerase Chain Reaction 
The gene encoding the β1-subunit of Mtb RNAP (entry Rv0667, gene rpo B) was obtained 
from the Tuberculist database (http://tuberculist.epfl.ch/). To ensure the optimal choice of start 
and end codons for the construct, the Mtb RNAP β1 protein was aligned with Taq RNAP β1 in 
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) as the latter has successfully been 
cloned, produced and purified and used in structural analyses (Srivastava et al. 2013). The 
required gene construct was delimited and the percentage of rare codons calculated using 
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RACC (http://nihserver.mbi.ucla.edu/RACC/). Forward and reverse primers for Mtb-RNAP 
β1 (Table 2) were designed. The amplification reaction is described in Table 7. 
Table 7: Reaction Mixture for PCR Preparation 
Reaction components Volume (µL) Concentration 
10 x Phusion GC buffer  5 1 x 
Template DNA 2 100 ng/µL 
Forward primer  1 10 pmol/µL 
Reverse primer  1 10 pmol/µL 
dNTP mix  1 10 µM 
Phusion DNA polymerase  1 1 U 
Nuclease free water 34 
 
Total volume 50  
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Table 8: PCR Reaction Programme 
PCR Step Purpose Temperature Duration 
Step1 Initial denaturation 98 C 1 min 
Step2* Denaturation 98 C 30 s 
Step3* Annealing 50 C  30 s 
Step4* Elongation 72 C 1.5 min 
Step5 Final elongation 72 C 10 min 
*Steps 2-4 were repeated 35 times 
The control experiment without primers was run alongside. 
2.4.2 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is used to analyse DNA samples. In this study, 1 % (w/v) agarose 
gels were prepared by dissolving 0.5 g agarose in 50 mL Tris-acetate-EDTA (TAE) buffer 
(Table 6) brought to boil in a microwave for 1 min. The agarose solution was allowed to cool 
to ~60 °C and 3 x SYBR Green was added as a fluorescent dye to visualize the DNA samples. 
The samples were prepared by mixing 4 µL of 10 % loading buffer (10 x) (Table 6) and 
10 µL of DNA (For all DNA samples in this study). This 14 µL mixture was loaded into a 
sample well, the gel was electrophoresed at 80 V and 2 mA for 60 min before being visualized 
and photographed under a UV illuminator. 
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2.6.3 Restriction Free Cloning 
Restriction free (RF) cloning is a method whereby a gene of interest may be inserted at any 
desired location into a circular plasmid, independent of restriction sites, ligation or any 
modifications in both vector and gene (Ent & Löwe 2006; Ulrich et al. 2012).  
The PCR reaction was planned in two phases. First, Mtb rnaP β1 was to be amplified from 
Mtb genomic DNA (kindly provided by Mr. Zhuo Fang, PhD student, Stellenbosch 
University). The reaction mixture and PCR programme are identical to conventional PCR as 
outlined in Tables 7 and 8. Second, the amplified product was to be inserted in the vector 
pGEX-6P-2. The reaction mixture for this second phase of RF cloning is summarized in Table 
9. The PCR programme is the same as that in Table 8 apart from the annealing temperature 
being changed to 62 C as suggested by the RF server. 
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Table 9: Reaction Mixture for RF Second Phase 
Reaction components Volume (µL) Concentration/Amount 
5 x Phusion GC buffer  5 1 x 
First phase product DNA 10 100 ng/µL 
dNTP mix  1 10 µM 
pGEX-6P-2 3 50 ng/µL 
Phusion DNA polymerase  1 1 U 
Nuclease free water 33 
 
Total volume 50  
 
To optimise the PCR conditions for the RF and the conventional PCR, the annealing 
temperature was varied using gradient PCR. The PCR reaction mixture and running 
programme remained the same as Tables 7 and 8 respectively except that the annealing 
temperature ranged from 45 to 65 C. The primers designed for the conventional PCR (Table 
2) were used to amplify from the PCR product of the RF first phase providing a higher 
concentration of template as compared to the genomic DNA. While the reaction mixture 
remained the same, a two-step PCR was used for amplification in the thermocycler (Table 
10). 
 
 
 
 
23 
 
Table 10: Two Step PCR Reaction Programme 
PCR Step Purpose Temperature Duration 
Step 1 Initial denaturation 98 C 30 s 
Step 2* Denaturation 98 C 10 s 
Step 3* Elongation 72 C 35 s 
Step 4 Final elongation 72 C 10 min 
*Steps 2-3 were repeated 35 times. 
All amplified products were analysed by agarose electrophoresis. 
2.6.4 Site Directed Mutagenesis 
Site directed mutagenesis (SDM) is used to replace, delete or insert nucleotides in a target 
DNA by combining PCR with appropriately designed primers. After amplification, the 
methylated parental DNA is digested by DpnI for 1 h at 37 °C to ensure that only the product 
DNA is present for downstream applications.  
To study the source of CarD instability, the N-terminal domain (CarDN) was to be produced 
and analysed independently of the C-terminal domain. To generate a corresponding gene 
construct, a stop codon (TAA) had to be introduced between the coding regions for the N- and 
the C-terminal domains. Secondary structure prediction was used to identify a suitable 
position and to ensure that the stop codon would not interrupt an α-helix or β-strand. The 
primers for CarDN (Table 2) were designed to insert a stop codon (TAA) between codons 64 
and 65 of carD. The mutation was undertaken by SDM using the Quick Change Kit 
(QIAGEN). The PCR reaction components were as follows: 
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Table 11: Reaction Mixture for SDM PCR 
Reaction components Volume (µL) Concentration 
10 x PCR buffer  5 1 x 
CarD plasmid DNA 1 85 ng/ µL 
Forward primer  1 0.2 µM 
Reverse primer  1 0.2 µM 
MgSO4 1 1.0 mM 
dNTP’s mix  1 0.2 mM 
KAPA HIFI DNA polymerase  1 1 U 
Nuclease free water 39 
 
Total volume 50  
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The PCR conditions in Table 12 were used for the CarDN SDM. 
Table 12: PCR Reaction Programme 
Step 1 Initial denaturation 95 C 60 s 
Step 2* Denaturation 95 C 40 s 
Step 3* Annealing 72 C  40 s 
Step 4* Elongation 74 C 6 min 
Step 5 Final elongation 74 C 8 min 
*Steps 2-4 were repeated 20 times 
  
 
The β1-subunit of RNAPs consists of two distinct domains β1a and β1b, where β1b was 
evolutionarily inserted into β1a. The orientation of β1b relative to β1a requires other subunits 
of the RNAP complex to stabilize (Westblade et al. 2010; Srivastava et al. 2013). To produce 
a minimal, conformationally stable Mtb RNAP β1, the had to be replaced by a glycine-glycine 
(GG) linker in analogy to Taq RNAP β1 (Westblade et al. 2010; Srivastava et al. 2013). Here 
SDM was chosen to potentially achieve the substitution in a single step. The conditions used 
are identical to Tables 11 and 12. This minimized RNAP β1 is denoted RNAP β1m. 
2.6.5 Cloning 
The amplified Mtb rnaP β1 product as well as pGEX-6P-2 was double digested with NotI and 
BamHI to create compatible sticky ends. The resulting fragments were analysed by agarose 
electrophoresis (Section 2.3.2). 
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Table 13: Double Digest of the Amplified rnaP β1 Gene 
Reagent Volume (µl)  Final concentrations/amount 
dsH2O 13 -
10 x Fast Digest enzyme Buffer 2 1 x
Amplified rnaP β1 DNA product 4 1 µg
NotI 0.5 5 U 
BamHI 0.5 5 U
 
The same experiment was set up for the pGEX-6P-2 plasmid DNA digest except that 3 µg of 
DNA were used rather than 1 µg. 
The reaction as outlined in Table 14 was used to ligate the insert to pGEX-6P-2. 
Table 14: The Ligation Reaction Between rnaP β1 and pGEX-6P-2 Plasmid DNA 
Reagent Volume (µl) Final concentration 
5 x Ligase Reaction Buffer  4  1 x 
Insert 9 17 ng/µl 
Plasmid  3 6 ng/µl 
T4 DNA ligase 0.5 0.1 U 
dsH2O 3.5 - 
 
The ligation mixture was incubated for 3 h at room temperature before transformation. 
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2.6.6 Transformation of Competent Bacteria 
Competent E. coli DH5α and E. coli BL21+, and/or Rosetta 2 cells were transformed with 
recombinant plasmid DNA for plasmid amplification and recombinant gene expression 
respectively (see below). Positive clones were selected for plating the transformation mixture 
on LB agar plates containing antibiotics corresponding to plasmid resistance genes.  
2.6.6.1 Heat Shock Method 
Plasmid DNA (1 µL) obtained from ligation reactions was added to 50 µL of competent cells 
thawed on ice. The cells were incubated on ice for 30 min and heat shocked for 45 s at 42 °C, 
followed by fast cooling on ice for 2 min. 800 µL of LB medium was added to the cells and 
the suspension shaken at 37 °C for 1 h on a thermo-mixer. The cells were gently resuspended 
using a 1 mL pipette. The transformation mixture was evenly spread on LB agar plates 
containing 0.1 µg/mL ampicillin using sterile glass beads. The plates were incubated at 37 °C 
overnight. 
2.6.6.2 Plasmid DNA Extraction 
An isolated colony from transformed E. coli cells were transferred to 5 mL of LB medium 
with 0.1 µg/mL ampicillin and allowed to grow at 37 °C with constant shaking overnight. 
Plasmid DNA was isolated using GeneJET mini prep kit as per manufacturer’s instructions. 
The concentration of eluted DNA was measured by reading absorption at 260 nm (A260) using 
a Nanodrop ND-1000 spectrophotometer. 
2.6.6.3 DNA Sequencing 
All the newly cloned plasmids in this work were sequenced by Inqaba Biotech using the 
Sanger chain sequencing method. 10 µL of the extracted plasmid DNA was pipetted into an 
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Eppendorf tube, labelled and sent for sequencing. The results were annotated using the 
BioEdit software package. 
2.6.7 Preparation of Glycerol Stocks 
Glycerol stocks were prepared for long-term storage of the cells (BL21+ and Rosetta 2) 
containing plasmids of interest from the transformation described in section 2.3.6.1. 5 mL LB 
medium was inoculated with the colony of transformed bacteria. After ampicillin (final 
concentration = 0.1 µg/mL) was added, the culture was grown to mid log phase (OD600 = 0.4 -
0.8) by incubating overnight at 37 °C at 160 rpm. Thereafter, 800 μL of the culture was mixed 
with 200 μL of sterile 80 % (v/v) glycerol (cryoprotectant) in a 1 mL cryo-vial. The vial was 
capped tightly and inverted several times for good mixing before being stored at -80 °C.  
2.7 Protein Production and Purification 
2.7.1 Pre-culture Preparation 
50 mL of autoclaved LB was pipetted into a sterile 100 mL Erlenmeyer flask. This was 
supplemented with 0.1 µL/mL of an appropriate antibiotic for selecting cells containing the 
transformed plasmid. An autoclaved pipette tip was used to scratch the frozen glycerol stock 
of transformants from -80 °C freezer and dropped inside the Erlenmeyer flask with 50 mL LB. 
The covered flask was incubated at 37 °C shaking at 180 rpm overnight.  
2.7.2 Main-culture Preparation 
The 100 µL pre-culture was mixed with 900 µL of sterile LB in a cuvette. The absorbance 
was measured to calculate the volume of pre-culture to add to the main-culture to obtain a 
starting absorbance OD600 = 0.1. The formula C1V1 = C2V2 was used, where C and V stand for 
concentration and volume, and subscripts 1 and 2 denote initial and final states, respectively. 
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Ampicillin was added to a final concentration of 0.1 µM/mL. The main-culture was incubated 
at 37 °C until it reached an OD600 of between 0.4 and 0.8 (log growth phase). Gene expression 
was induced by adding 100 µL/1 L (0.1 mM) of isopropyl β-D-1-thiogalactopyranoside 
(IPTG).  
Cultures were incubated overnight at 16 °C and 180 rpm for pGEX-6P-1-CarD and pGEX-6P-
2-CarDN. For pGEX-6P-2_Mtb-RNAP β1m and pET28a_Taq-RNAP β1m, the temperature was 
adjusted to 25 °C. After overnight incubation, cells were harvested by centrifugation at 7600 
relative centrifugal force (rcf) and 4 °C for 15 min. The supernatant was discarded and the cell 
pellets resuspended in 20 mL lysis buffer per 1 L culture at 4 °C. 
2.7.3 Sonication of Cells 
To inhibit host serine proteases, phenylmethanesulfonylfluoride (PMSF) was added to the 
resuspended cells for a final concentration of 0.5 mM prior. Cells were lysed by sonication 
using 5 cycles of 30 s sonication separated by 30 s breaks on ice to prevent denaturing of 
protein. To degrade genomic DNA, 0.32 µg/mL of DNAse I (20 µL of a 0.4 mg/L stock) was 
added to the disrupted cells and incubated on ice for 20 min. The disrupted cells were then 
transferred to pre-chilled SS34 tubes and soluble protein separated from cell debris and other 
insoluble proteins by centrifugation at 29000 rcf for 60 min at 4 °C using an SA-600 rotor in a 
RC6 Sorvall centrifuge. 
2.7.4 Protein Purification 
Proteins were purified using different methods (see below). To assess the protein purity in this 
study, 15 % sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) was used. 
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2.7.4.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
Protein samples were mixed with 8 x sample buffer (10 L protein + 3 L sample buffer). For 
protein denaturation, samples were heated to 95 °C for 5 min. The protein samples were 
pipetted into a loading pocket of the gel and electrophoresed at 40 mA for 40 to 45 min. The 
gel was stained for 15 to 20 min in a Coomassie Brilliant Blue R-250 solution and excess stain 
removed by incubating in a destaining solution overnight at room temperature. 
2.7.4.2 Affinity Chromatography 
Affinity chromatography utilizes strong and specific binding of affinity tags fused to the N- or 
C-terminus of the target protein to an immobilized matrix. In this work, CarD, CarDN and Mtb 
RNAP β1m were produced as fusion proteins with an N-terminal glutathione-S-transferase 
(GST) tag, while Taq RNAP β1m was produced with an N-terminal hexahistidine tag (His6). 
CarD production and purification buffers were augmented with 5 % (v/v) glycerol to prevent 
degradation. 
2.7.4.2.1 Glutathione-S-Transferase Affinity Chromatography 
As CarD was produced as a GST fusion protein it could be purified using GST-affinity 
chromatography. The glutathione sepharose (GS) beads were equilibrated with 10 x bed 
volume of 1 x PBS pH 7.4, 5 % (v/v) glycerol in a 12 mL column. The centrifugation 
supernatant containing soluble CarD was added to the equilibrated GS beads in a 50 mL 
Falcon tube and incubated at 4 °C on a roller mixer for 4 h to allow coupling of the fusion 
protein to the matrix. Unbound proteins and cell debris were eluted in a fraction labelled 
“flow-through”. The beads were washed by adding 10 mL PBS with 5 % (v/v) glycerol to the 
column and allowing the buffer to elute. This was repeated 5 times. CarD-bearing beads were 
equilibrated with 10 mL cleavage buffer. The beads were resuspended in 5 mL of this buffer 
 
 
 
 
31 
 
by gentle inversion and 200 µL of PreScission cleavage protease was added to the beads and 
the mixture incubated overnight at 4 °C on a roller mixer. CarD was eluted from the GS beads 
with CarD purification buffer and fractions analysed by 15 % SDS-PAGE. 
The same protocol was used to purify CarDN and Mtb-RNAP β1m except that buffers were not 
augmented with 5 % (v/v) glycerol. 
2.7.4.2.2 Nickel-NTA Affinity Chromatography 
Nickel-nitrilotriacetic acid (Ni2+-NTA) agarose beads are used to purify recombinant proteins 
fused to His6-tags. The histidine residues bind to the immobilized Ni2+ with high specificity 
and affinity. His6-tagged Taq RNAP β1m was recovered from the bacterial host cells by cell 
disruption and centrifugation as described for CarD. 1.5 mL resuspended Ni2+-NTA beads 
were equilibrated with 100 mL 1 x PBS pH 7.4 in a drip column. The soluble protein fraction 
was added to the beads in a 50 mL Falcon tube and incubated at 4 °C on a roller mixer for 4 h. 
The suspension was poured back into the column and the flow-through eluted and collected to 
check for the presence of unbound fusion protein. The beads were washed five times with 
10 mL of 1 x PBS pH 7.4 with 10 mM imidazole. Taq RNAP β1m was then eluted with 1 x 
PBS pH 7.4, 250 mM imidazole in five 10 mL fractions and the purity analysed by SDS-
PAGE. Taq RNAP β1m was further purified with size exclusion chromatography (SEC). 
2.7.2.3 Ion Exchange Chromatography 
Ion exchange chromatography separates protein samples based on their electrostatic 
properties. In cation exchange chromatography, positively charged protein molecules bind to a 
negatively charged resin and vice versa for anion exchange. After the protein of interest has 
bound to the beads, all unbound proteins are removed by washing with low ionic buffer.  After 
binding and washing, the bound proteins are eluted by linearly increasing NaCl concentration. 
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CarD and CarDN were both purified by anion exchange chromatography using a MonoQ HR 
10/100 GL column (GE Healthcare) on an ÄKTA purifier (GE Healthcare). Protein samples 
were dialyzed against buffer A (Table 6) overnight using 35 kDa MWCO snake skin pleated 
dialysis tubing (Thermo Scientific). The column was prepared by spiking it with 20 mL of 2 
M NaCl to displace all other ions and then equilibrating with buffer A (Table 6). Samples 
were loaded onto the MonoQ column and differentially eluted using a linear gradient of 
increasing high salt buffer B (Table 6) at a constant flow rate of 0.5 mL/min. Fractions 
corresponding to absorption peaks were analysed by SDS-PAGE. 
2.7.2.4 Size Exclusion Chromatography 
Size exclusion chromatography (SEC) – also known as gel permeation chromatography or gel 
filtration - separates proteins based on their molecular size. In this study, Taq RNAP β1m was 
purified by SEC. The protein was concentrated until 1 mL using a 10 kDa MWCO vivaspin 
concentrator. A Superdex 75 16/60 column (bed volume 24 mL) was equilibrated with 2 
column volumes of degassed running buffer (1 x PBS pH 7.4) on an ÄKTA purifier at 10 °C. 
800 µL of protein sample was injected onto the column at a flow rate of 0.5 mL/min and the 
elution profile was monitored at 280 nm. Peak fractions were analysed by SDS-PAGE. 
2.8 Pull-Down Experiments 
This assay involves the immobilization of one protein (bait) of a suspected protein-protein 
interaction on a matrix through an affinity tag and the selective retention of a second protein 
(prey) through their direct interaction. 
2.8.1 Glutathione-S-Transferase Pull Down 
Here GST-CarD and GST-CarDN were used as bait while Taq RNAP β1m was used as prey. 
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2.8.2	Ni2+‐NTA	Pull	Down	Assay	
 
His6 tagged Taq RNAP β1m was immobilized on Ni2+-NTA beads while CarD and CarDN were 
used as prey. 
Optimal complex formation for CarD/Taq RNAP β1m and CarDN/ Taq RNAP β1m were tested 
by using buffers and salt conditions outlined in Table 15. 
Table 15: Conditions Explored for Optimal CarD/RNAP Complex Formation 
Buffer 
Acetate MES/NaOH PBS Tri-HCl Glycine-
NAOH 
Glycine-
NAOH 
Concentration 50 50 1 x 150 100 100 
pH 5 6  7.4 8 9 10 
NaCl 200 50 40 150 100 30 
Na2HPO4 0 100 50 150 10 20 
Li2S04 10 5 50 20 40 0 
Glycerol 5 5 5 5 5 5 
Concentrations in mM, except PBS (1 x) and glycerol (% v/v). 
2.8.3 Small Scale Pull Downs 
All proteins were purified by affinity chromatography using appropriate matrices for each tag 
– GS beads for GST and Ni-NTA beads for His6. Bead samples for each protein were split 
into two equal parts A (bait) and B (prey). Part A was split into six equal fractions in 1.5 mL 
Eppendorf tubes and each incubated for 5 min with 500 µL of one buffer from Table 15. 
Tubes were centrifuged at 10500 rcf and the supernatant discarded. B fraction proteins were 
cleaved/eluted and purified as outlined above and concentrated to 10 mg/mL using a 10 kDa 
MWCO Vivaspin concentrator. The purified protein fractions were centrifuged at 10500 rcf 
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for 10 min to remove precipitates, divided into six equal divisions and added to A fraction 
subdivisions of its corresponding bait protein. 500 µL of corresponding buffers from table 15 
were added to respective bait/prey mixture tubes. The bait/prey mixtures were incubated for 4 
h at 4 °C on a roller mixer, centrifuged at 10500 rcf and the bead supernatants carefully 
removed by pipette and transferred to a separate tube. Beads were washed with respective 
designated buffers by centrifugation at 10500 rcf. For Ni2+-NTA bait protein, potential protein 
complexes were eluted with 500 µL of 1 x PBS, 250 mM imidazole. GST-tag bait protein was 
cleaved by adding 50 µL PreScission protease, incubating overnight at 4 °C on a roller mixer 
and eluting by centrifuging at 10500 rcf at 4 °C for 3 min. This was repeated twice. Samples 
were analysed in 15 % SDS-PAGE. 
2.8.4 Large Scale Pull Downs 
For large-scale interaction studies of CarD and CarDN with Taq RNAP β1m, production was 
scaled up to 1 L. To allow optimal protein interaction, 1 x PBS pH 7.4 with 5 % (v/v) glycerol 
was used as this buffer most closely resembles physiological cytosolic conditions. In contrast 
to the preceding section, GS beads from 1 L cultures were not subdivided. Washing and 
elution steps were repeated 5 times with 10 mL of buffer each time. Instead of centrifugation, 
the buffer was allowed to elute from the drip column and collected for analysis by 15 % SDS-
PAGE. Before adding Taq RNAP β1m to GST-CarD or GST-CarDN, it was purified by SEC. 
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3.0	Results	
3.1 RNAP β1 Delimitation 
 
At the start of this project, clones for the production of Mtb CarD and Taq RNAP β1m were 
available. However, as the two proteins derive from different organisms, data obtained for 
their interaction may be of limited value in assessing the interaction of the corresponding 
physiological complex. To overcome this limitation, a clone for the production of Mtb RNAP 
β1m had to be prepared by amplifying the corresponding gene fragment from genomic DNA 
(Westblade et al. 2010). 
 
Figure 2: The Mtb Gene for RNAP 
A: Amino acid sequence for Mtb RNAP β1 from Tuberculist. The central green highlighted 
region corresponds to the β1b domain that was to be replaced by a GG-linker to obtain the 
minimal, conformationally stable Mtb RNAP β1m as previously done for Taq RNAP β1.  
B: An amino acid sequence alignment of Taq RNAP β1m and Mtb RNAP β1m (ClustalW). 
The inserted GG dipeptides (red and green) connect the N- and C-terminal parts of the β1a 
domains of Taq RNAP β1 and Mtb RNAP β1 respectively, after removal of the β1b domain. 
Symbols *, : and . indicate residues, which are conserved, semi conserved or only similar 
for the two proteins. Spaces indicate non-conserved residues. 
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The amino acid sequence of Mtb RNAP β1 domain is shown in Figure 2A. As outlined in 
section 2.6.4, the domain β1b (green in Figure 2A), that has evolutionarily been inserted into 
the β1a domain had to be replaced by a GG linker (Figure 2B) to generate a conformationally 
stable Mtb RNAP β1m protein. The sequence alignment indicates numerous sequence 
differences for Mtb RNAP β1m and Taq RNAP β1m (Figure 2B) which may dramatically 
affect the interaction with Mtb CarD. 
 
 
 
 
Figure 3: Rare Codon Usage 
The DNA sequence for Mtb RNAP β1 domain highlighting rare codons with respect to translation in E. coli. 
Rare codons for isoleucine, arginine and proline are respectively colored blue, red and orange 
   
Mtb rnaP gene 
 
gga ctc ctt gac gtc cag acc gat tcg ttc gag tgg ctg atc ggt tcg ccg 
cgc tgg cgc gaa tcc gcc gcc gag cgg ggt gat gtc aac cca gtg ggt ggc 
ctg gaa gag gtg ctc tac gag ctg tct ccg atc gag gac ttc tcc ggg tcg 
atg tcg ttg tcg ttc tct gac cct cgt ttc gac gat gtc aag gca CCC gtc 
gac gag tgc aaa gac aag gac atg acg tac gcg gct cca ctg ttc gtc acc 
gcc gag ttc atc aac aac aac acc ggt gag atc aag agt cag acg gtg ttc 
atg ggt gac ttc ccg atg atg acc gag aag ggc acg ttc atc atc aac ggg 
acc gag cgt gtg gtg gtc agc cag ctg gtg cgg tcg CCC ggg gtg tac ttc 
gac gag acc att gac aag tcc acc gac aag acg ctg cac agc gtc aag gtg 
atc ccg agc cgc ggc gcg tgg ctc gag ttt gac gtc gac aag cgc gac acc 
gtc ggc gtg cgc atc gac cgc aaa cgc cgg caa ccg gtc acc gtg ctg ctc 
aag gcg ctg ggc tgg acc agc gag cag att gtc gag cgg ttc ggg ttc tcc 
gag atc atg cga tcg acg ctg gag aag gac aac acc gtc ggc acc gac gag 
gcg ctg ttg gac atc tac cgc aag ctg cgt ccg ggc gag CCC ccg acc aaa 
gag tca gcg cag acg ctg ttg gaa aac ttg ttc ttc aag gag aag cgc tac 
gac ctg gcc cgc gtc ggt cgc tat aag gtc aac aag aag ctc ggg ctg cat 
gtc ggc gag CCC atc acg tcg tcg acg ctg acc gaa gaa gac gtc gtg gcc 
acc atc gaa tat ctg gtc cgc ttg cac gag ggt cag acc acg atg acc gtt 
ccg ggc ggc gtc gag gtg ccg gtg gaa acc gac gac atc gac cac ttc ggc 
aac cgc cgc ctg cgt acg gtc ggc gag ctg atc caa aac cag atc cgg gtc 
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The gene construct encoding Mtb RNAP β1 contains six codons considered rare in E. coli 
including four proline codons (Figure 3). Generally, mRNA with less than ten rare codons 
should allow for unhindered translation in BL21 and BL21+ cells (Berg & Silva 1997). 
3.1 Amplification of Mtb rnaP β1 Gene 
 
Two distinct cloning strategies were followed to amplify the Mtb rnaP β1 gene – restriction 
free (RF) and conventional (normal) PCR (Figure 4). The reason for trying two alternative 
methodologies is that amplification of genes from GC-rich Mtb genomic DNA frequently 
 
 
Figure 4: Amplification of Mtb rnaP β1 Gene from Genomic DNA 
A Lane 1: 1 kb gene ladder. Lane 2: Product from conventional PCR. The expected PCR product of a 
1000 bp is not observed. Lane 3: Successful first phase PCR product from genomic DNA for restriction-free 
(RF) cloning marked by a yellow circle. Lanes 4 and 5: Control experiments for conventional and RF PCR, 
run without primers. No amplification is observed, as expected.  
B, Lane 1: 1kb gene ladder; Lane 2: Repeat of the RF first phase amplification. The successful product is 
marked by a yellow circle. Lane 3: Control without primers. C: 1kb gene ladder 
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proves difficult in practice. Following a double track strategy increases the likelihood of 
achieving successful amplification. 
Attempts to amplify the Mtb rnaP β1 gene from genomic DNA by conventional PCR were not 
successful for the annealing temperature of 50 C (Figure 4A, lane 2). The gene of interest is 
1167 nucleotides long and should hence be visible just above the 1000 bp band of the DNA 
standard. By contrast, the RF first phase PCR successfully (Figure 4A Lane 3: band within 
yellow circle) and reproducibly (Figure 4B, band within yellow circle) amplified the gene 
from the same genomic DNA at the same annealing temperature. 
3.1.1 Gradient PCR 
 
To improve the product yields for the RF first phase PCR, the experimental conditions were 
optimized. Figure 5 documents the yields for different annealing temperatures. 
 
Figure 5: Annealing Temperature Gradient for RF PCR First Phase 
Lane 1: 1 kb Marker. Lanes 2-13: PCR products for temperatures 45.0, 46.3, 47.2, 49.9, 52.8, 55.7, 57.0, 
59.6, 62.9, 63.8, 64.4 and 65.0 C. The product lies between has a size between 1500 and 1000 bp. The 
amplification was successful for all temperatures except for 62.9 C and 65.0 C. However 63.8 C as 
shown by yellow circle, shows the best result. 
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The RF first phase PCR yielded the expected products for all annealing temperatures tested 
but with the highest yield recorded for 63.8 C (Figure 5, band marked by yellow circle, size 
1167 bp). Conventional PCR by comparison did not yield an amplified DNA product for all 
temperatures between 45.0 and 65.0 °C. To proceed with conventional PCR, the RF first 
phase PCR product (yellow circle, Figure 5) was used as template DNA for conventional 
PCR. This worked particularly well resulting in higher yields of PCR product (Figure 6, lane 
3) than RF PCR (Figure 6, lane 2): 200 ng/µL for conventional PCR of compared to 124 
ng/µL for RF. 
 The product of conventional PCR (Figure 6, lane 3) was successfully digested by restriction 
enzymes, ligated to expression plasmid, and transformed into DH5α cells. The successful 
incorporation was confirmed by Sanger sequencing: Figure 7 illustrates the the beginning of 
 
Figure 6: Amplification of rnaP β1 Gene from RF Product 
Lane 1: 1kb gene ladder; Lane 2: RF phase one PCR product amplified from genomic DNA (left red arrow); 
Lane 3: conventional PCR product amplified from RF product using a two-step PCR (right red arrow); Lane 
4: Control without DNA polymerase 
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the corresponding chromatogram. By contrast, the second phase of RF PCR, incorporation of 
target gene into the production plasmid, was not successful. However, as the target of the 
experiment had been achieved in the successful cloning of Mtb RNAP β1, the RF cloning 
strategy was not pursued any further. 
Sanger sequencing from the 3’ end of the target gene confirmed the first 800 nucleotides of 
the gene. Diminishing signals thereafter yielded increasingly ambiguous results, as is typical 
for this technique. A second sequencing reaction from the 5’ end complemented the missing 
data confirming the correct amplification and incorporation of the entire Mtb rnaP β1 gene 
into the expression vector. 
3.1.2 Generation of the CarDN 
 
To yield a GST-tagged CarD fusion protein, the carD gene had previously been cloned into 
the multicloning site of pGEX-6P-1 (Lilia Polle, personal communication) using the 
restriction enzymes BamHI and NotI and incorporating two stop codons before the NotI 
 
Figure 7: The Sanger Sequencing Chromatogram of rnaP β1 
The first 20 nucleotides of the gene rnaP β1 are highlighted by black shading with the 3’ end being pointed 
out by a large arrow marks. Each colour codes for one of the four nucleotides. The sharp peaks are sharp 
unambiguously providing the anticipated nucleotide sequence.  
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restriction site. A PreScission protease cleavage site encoding sequence in the pGEX-6P-1 
vector precedes the BamHI restriction site. Figure 8 provides a schematic representation of  
the carD construct in pGEX-6P-1 for production in E. coli. 
 
To generate a construct that will produce the GST-tagged N-terminal domain of CarD 
(CarDN), a stop codon was inserted between codons 64 and 65 of carD by SDM. The PCR 
product for this reaction was not visible in an agarose gel. The ligated product was, however, 
transformed into Gene Hog cells, which upon cultivation, cell lysis, DNA isolation and Sanger 
sequencing confirmed the incorporation of the TAA stop codon at the expected position.  
3.2 CarD purification 
 
A one-step purification of CarD by GST affinity chromatography produced fairly pure CarD 
as evaluated by 15 % SDS-PAGE gel (Figure 9). This protein was observed to degrade within  
two days presumably due to the presence of host-strain specific proteases. This degradation 
limited progress of further experiments. After testing a range of inhibitors and other additives, 
5 % (v/v) glycerol was found to extend the lifetime of CarD to at least 67 days when added to 
both purification and storage buffers. 
 
 
Figure 8: Schematic Representation of the carD Gene Construct 
Green, orange and white rectangles respectively represent GST, PreScission Protease Cleavage (PPC) site and 
CarD encoding regions. Red and yellow bars indicate BamHI and NotI restriction sites, respectively. The two 
stop codons prior to the NotI restriction site are marked in blue.  
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CarD production and purification is demonstrated in Figure 9. The GST-CarD fusion protein 
is highlighted by yellow boxes. The fusion protein is evident in the soluble fraction (lane 4) 
but not in the insoluble fraction (lane 5) implying that it is highly soluble. Following removal 
of unbound or non-specifically bound proteins from the column (lane 10), and proteolytic 
 
Figure 9: SDS-PAGE Analysis of CarD Purification 
Lane 1: Prestained protein marker; Lane 2: E. coli full-cell sample prior to IPTG induction; Lane 3: 16 h after 
induction; Lane 4 Soluble fraction sample after centrifugation at 29000 RCF at 4 C; Lane 5: Urea-solubilized 
insoluble fraction after centrifugation; Lane 6: Elution of non-coupled proteins after coupling to GS beads for 
4 h; Lanes 7 and 8: Wash fractions after washing with 10 mL of 1 x PBS pH 7.4; Lane 9: Clean GS beads before 
adding the soluble cell fractiond; Lane 10: GS beads after elution of unbound protein; Lane 11: Partly cleaved 
fusion protein with PreScission protease. Most fusion protein is still uncleaved; Lanes 12 to 15: CarD elution 
fractions. Yellow, purple and red boxes and arrows indicate GST-CarD fusion protein, GST and CarD, 
respectively. 
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separation of GST and CarD by PreScission protease (lane 11), GST (purple box) remains 
bound to the glutathione sepharose. Clearly, cleavage is fairly slow as most fusion protein is 
still intact (fusion protein band in lane 11 is essentially indistinguishable from that in lane 10 
18 h after adding the protease). The small amount of eluted CarD (Figure 9, red boxes in 
lanes 12 to 15 was, nevertheless, fairly pure with small contaminants of fusion protein and 
another protein around 70 KDa. 
Pooling all fractions of eluted CarD (lanes 12-15, Figure 9) yielded a total of 6 mg CarD – 
clearly only a small fraction of the entire protein produced. Anion exchange purification was 
then attempted using a MonoQ column to remove the remaining impurities. The protein was 
injected onto the column under low salt conditions, resulting in most CarD binding as 
evidenced by the lack of a peak during the loading phase (Figure 10A). CarD was then eluted 
with a linear salt gradient ranging from 0 to 20 % buffer B (0 to 0.2 M NaCl). Although a 
strong peak is clearly visible in the elution curve (Figure 10A), fractions corresponding to this 
peak do not reveal a protein band for CarD in the corresponding 15 % SDS-PAGE (Figure 
10B), implying that CarD is destabilized or unfolded by the anion exchange column resulting 
in its rapid degradation.  
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. 
3.3 Purification of the CarDN 
 
As the construct for the CarDN retains the original N-terminal GST-tag, the purification 
strategy for this domain was identical to that of the full-length protein. The outcome is shown 
in Figure 11 below. 
 
Figure 10: Anion Exchange Chromatography of CarD 
A) Anion exchange chromatogram for CarD (blue) showing a peak presumably corresponding to eluting CarD at 
a buffer B concentration of ~12%. Absorbance is given in milli absorbance units (mAU). The green line plots 
the theoretical linear gradient of buffer B in %. 
B) A 15 % SDS-PAGE analysis of fractions corresponding to the peak in A. Unexpectedly no protein bands are 
visible implying that protein is rapidly degraded after elution from the column 
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GST-CarDN, like GST-CarD is a highly soluble fusion protein of ~35 kDa (Figure 11, Lane 5 
but not visible in lane 6, insoluble fraction). Proteolytic cleavage of GST-CarDN fusion 
protein is significantly faster than that of CarD (Figure 11, lane 10). CarDN was stable for 
more than 20 days in PBS pH 7.4. Eluted CarDN was, however, not as pure as CarD (Figure 9 
lanes 12 and 13). The total yield of CarD (Figure 11, lanes 12 – 15) was 3.2 mg. 
 
Figure 11: SDS-PAGE Analysis of the Affinity Purification of the CarD N-terminal Domain 
Lane 1: Prestained protein marker; Lane 2: Full-cell sample prior to induction with IPTG; Lane 3: Full-cell 
sample 16 h after induction; Lane 4: Soluble fraction; Lane 5: Urea-solubilized insoluble fraction; Lane 6: GS 
beads after protein coupling; Lanes 7 and 8: Wash fractions after washing GS beads with 20 mL PBS pH 7.4. 
Lane 9 and 11: GS beads before and after coupling CarDN; Lane 10: GST remaining attached to beads after 
cleavage and elution of CarDN; Lanes 12-15: Eluted CarDN. Yellow and red boxes and arrows mark GST-CarDN 
and CarDN. 
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As described for full-length CarD above, purification of CarDN by anion exchange 
chromatography (Figure 12A) allowed for the binding and specific elution of the protein from 
the column. However, again the protein was rapidly degraded such that no protein bands were 
visible in the SDS-PAGE analysis as indicated in Figure 12B below. 
3.4 Production and Purification of RNAP β1 
 
Despite the successful cloning of Mtb rnaP β1 gene and the transformation of the plasmids 
into BL21+ and Rosetta 2 cells, induction of recombinant protein production by IPTG did not 
result in observable production of the Mtb RNAP β1. The results for expression trials in 
BL21+ cells are documented in Figure 13. 
 
Figure 12: Anion Exchange Chromatography of CarDN 
A) Anion exchange chromatogram for CarD (blue). An absorption peak is observed that presumably corresponds 
to eluting CarDN at a buffer B concentration of ~13%. Absorbance (y-axis) is in milli absorbance units (mAU). 
The x-axis corresponds to the NaCl concentration (in mM). 
B) A 15 % SDS-PAGE analysis of fractions corresponding to the peak in A. Surprisingly, no protein bands at 
about size 7 kDa (red arrow) are visible implying that protein is rapidly degraded after elution. 
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Unfortunately, Mtb RNAP β1 was not produced after inducing with 0.1 mM IPTG as samples 
from soluble and insoluble protein fractions 3, 10 and 16 h after induction indicate no increase 
in a band at the expected size (red arrow in Figure 13 A). Occasionally production levels of 
proteins can be too low to be visible on Coomassie stained SDS-PAGE. In such cases, 
produced proteins can be enriched using affinity chromatography to reveal residual protein 
production. The content of lysed cells 18 h after induction was therefore incubated with GS 
beads, eluted and the beads washed. However, samples of the beads do not indicate any fusion 
protein bound to the column (Figure 13 B), implying that.  
Nevertheless, Taq RNAP β1m produced and expressed solubly in BL 21 cells. Figure 14 
shows the purification results. 
	
 
Figure 13: Expression Tests for Mtb rnaP gene in BL21+ Cells 
A) Lane 1: Unstained protein marker; Lane 2-5: Soluble fractions respectively 0, 3, 10 and 16 h after induction 
with 0.1 mM IPTG; Lane 6: Insoluble fraction prior to induction; Lanes 7-9: Insoluble fractions respectively 3, 
10 and 16 h after induction. The red arrow marks the expected size of the GST-RNAP β1 fusion protein at 70 
kDa. B) Lanes 1 and 2: GS beads before and after addition of the soluble fraction; 3: Clean GS beads. 
 
 
 
 
 
48 
 
	
The Taq RNAP β1m comes out as early as wash step with buffer containing 10 mM imidazole. 
Almost all of the remaining Taq RNAP β1m was eluted by 10 mL of 250 mM imidazole 
containing buffer with just above 45 kDa contaminating protein (Figure 14 lane 7). The Taq 
RNAP β1m was further purified using SEC and was pure as analysed by 15 % SDS-PAGE gel 
(Figure 15) 
 
 
 
 
Figure 14: 15 % SDS-PAGE for Taq RNAP 
Lane 1: Unstainable protein marker, lane 2: proteins that did not bind to the Ni2+-NTA beads after incubation with 
soluble protein fraction. Lanes 3-6: wash fractions collected after Ni2+-NTA beads were washed with 40 mL of 
Ni2+-NTA wash buffer (Table 10). Lanes 7-10 are samples collected when Taq RNAP β1m was eluted with Ni2+-
NTA elution buffer. The red arrow shows the Taq RNAP β1m at 23 KDa 
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Taq RNAP β1m eluted from the GPC column in a broad peak covering 12 mL (Figure 15). 
The size corresponds to 23 kDa (red box and red arrow). The purity is improved compared to 
Ni2+-NTA affinity chromatography. The pooled samples contained a total of 30 mg of Taq 
RNAP β1m. 
3.5	CarD/RNAP	β1m	Complex	
 
As described in the Introduction (Section 1.5.2), CarD is assumed to bind to RNAP through 
its N terminal domain. To investigate and confirm this interaction, two pull-down assays were 
developed and applied (Figure 17).. In the first, Taq RNAP β1 (bait) is allowed to bind to 
 
Figure 15: Size exclusion chromatography purification of Taq RNAP β1m 
SEC of Taq RNAP primarily using PBS pH 7.4 reveals a single absorption peak at an elution volume of 12 mL, 
presumably corresponding to purified RNAP. Insert – SDS-PAGE analysis of the size exclusion purification. 
Lane 1: Molecular weight marker; Lanes 2 to12: samples from fractions within the absorption peak. Fractions 
with pure RNAP are marked by a red rectangle and a red arrow. 
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Ni2+-NTA whereupon CarD is added, incubated and analysed for binding (Section 2.5). In the 
second, GST-CarD (bait) is coupled to GS-beads and Taq RNAP β1 (prey) is added, incubated 
and tested for binding. Unexpectedly the former assay, Ni2+-NTA pull down, did not work. 
The pull-down assay using GST-CarD as bait confirms the expected stoichiometric (1:1) 
complex between CarD and Taq RNAP β1. 
 
Figure 17 depicts the results for the pull-down assays in the form of 15 % SDS-PAGE for 
complex formation according to the schematic diagrams in Figure 16 A. Conditions were 
varied to optimize CarD complex formation (Section 2.5.2). Preparation of both bait and prey 
proteins were described in the preceding sections (Figures 9, 11, 14 and 15).  
 
Figure 16: The Schematic Representation of Two Ways of Forming a CarD/RNAP Complex 
A) First, RNAP is allowed to bind to the Ni2+-NTA beads (bait) via its His6-tag. CarD (prey) is then added to the 
immobilized RNAP and incubated to allow complex formation – presumably via the N-terminal domain of CarD 
B) GST-CarD fusion protein (bait) is allowed to bind to GS beads via the GST domain. Taq RNAP β1m is then 
added to the immobilized CarD and incubated to allow complex formation between CarD and Taq RNAP β1m. 
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CarD eluted along with other unbound proteins after incubation with Taq RNAP β1m-loaded 
Ni2+-NTA beads for all conditions tested. CarD was also eluted during the washing steps – as 
was some of the Taq RNAP β1m (Figure 16A). When beads potentially bearing Taq RNAP 
β1m/CarD complexes were incubated with buffer containing 250 mM imidazole, only Taq 
RNAP β1m eluted (Figure 16B) and only RNAP remained on the beads (Figure 16C). This 
observation implied, that Taq RNAP β1m and CarD do not form a complex under the 
conditions tested here. To test whether this was always the case, the inverted experiment was 
 
Figure 17: 15 % SDS-PAGE results for Ni-NTA pull down experiments 
The number above each lane indicates the pH of the buffer used to form, purify and elute the complex from the 
Ni2+-NTA beads.  
A) Unbound proteins eluted after incubation of CarD with Ni-NTA/Taq RNAP β1m beads for 3 h using the 
indicated buffers. Red arrows mark Taq RNAP β1m (shown as RNAP in the picture) and CarD. 
B) Elution of potential Taq RNAP β1m/CarD complexes using the designated buffer enriched with 250 mM 
imidazole. The step was repeated to ensure complete elution of the coupled proteins. The red arrow marks eluted 
RNAP. 
C) Beads from B after elution. The red arrow marks RNAP remaining on the beads. 
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undertaken in which GST-CarD was coupled to the matrix and Taq RNAP β1m added to check 
for complex formation (Figure 17). 
Excess Taq RNAP β1m is seen to elute both in the flow through after incubating Taq RNAP 
β1m with GST-CarD complex coupled to GS-sepharose as well as in the following wash stages 
(Figure 17A). As expected, GST-CarD remains firmly attached to the GS beads, due to the 
high affinity of GST for GS. Following cleavage of the GST-CarD fusion protein by 
PreScission protease, Taq RNAP β1m and CarD are seen to elute in approximately 
stoicheometric amounts (Figure 17B), indicating that the proteins do form a complex. Note 
that this complex is observed for all tested buffer conditions. Optimal complex formation is 
 
Figure 18: GST-CarD/ Taq RNAP β1m Pull Down Assay 
The pH of the buffer used during incubation, purification and elution of potential GST-CarD/Taq RNAP β1m 
complex from GS beads is shown above each lane.  
A) Left half: Unbound protein eluted after incubating Taq RNAP β1m (labeled as just RNAP) with GST-CarD for 
3 h. Right half: Elution after beads washing to remove all unspecifically bound proteins. Excess Taq RNAP β1m 
elutes. 
B) Elution of CarD/Taq RNAP β1m complex after proteolytic release from GST bound to GS-beads with 
PreScission protease overnight. The beads were washed to ensure complete removal of released complex. Red 
arrows mark Taq RNAP β1m and CarD at 23 kDa and 18 kDa respectively. 
C) GS-beads after removal of CarD/Taq RNAP β1m. The red arrow marks GST remaining on the beads. 
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seen for PBS pH 7.4 buffer with 5 % (v/v) glycerol. The proteolytic release of CarD is seen to 
have worked quantitatively, with no fusion protein but only GST remaining on the beads 
(Figure 17C). 
Larger scale complex formation was attempted using PBS pH 7.4, 5 % (v/v) glycerol (Figure 
18). Only the elution of Complex was shown here. 
In contrast to the run in Figure 18, this round did not yield a 1:1 CarD/Taq RNAP β1m 
complex as evidenced by a weaker Taq RNAP β1m band (at ~26 kDa) compared to CarD 
(~20 kDa). A stoichiometric complex was recorded only for the first 10 mL (Figure 19, lane 
2). Lane 7 demonstrates that both GST-CarD fusion protein (45 kDa) and GST (25 kDa) 
remain bound to the column after elution sample.  
 
Figure 19: Large-scale Complexation of CarD/ Taq RNAP β1m 
M: Protein marker; Lanes 1-6: CarD/Taq RNAP β1m complex eluted from the GS beads following incubation in 
the presence of PBS pH 7.4, 5 % (v/v) glycerol. This complex was cleaved from the beads by PreScission 
protease overnight at 4 C; Lane 7: GS beads after complex elution 
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The complex CarDN/Taq RNAP β1m was produced similarly, using a GST pull down 
approach (Figure 20). 
 CarDN was produced as a GST-fusion protein (34 kDa, Figure 20A lane 6). In lane 7, Taq 
RNAP β1m is visible as a dark band at 23 kDa. The complex was noted as 2 bands before 
cleavage from the GS beads (Figure 20 lane 10) as shown by the circles even though the band 
associated with Taq RNAP β1m is not as bold as that of the CarDN fusion protein. However, 
the two proteins appeared in almost equal amounts after proteolytic release of the complex 
from the GS beads (Figure 20 B lane 1) as marked in red circles. No band was noted 
thereafter except for CarDN-GST fusion protein and GST still stuck on the GS beads after 
elution (Figure 20B lane 6).  
.  
 
Figure 21: Analysis of CarDN/ RNAP Complex 
A) Lane 1: Protein marker; Lane 2: Soluble fraction after coupling of CarDN to the GS beads; Lanes 3 to 5: Wash 
fractions to remove unbound proteins; Lane 6: GS beads after wash steps; Lanes 7 to 9: Removal of unbound 
proteins after incubating CarD and RNAP for 3 h; Lane 10: GS beads after elution of  Taq RNAP β1m /CarDN 
complex. Red circles mark Taq RNAP β1m and GST-CarDN fusion protein at 23 and 34 kDa respectfully. B) 
Lane 1: Protein marker; Lanes 2 to 5: Taq RNAP β1m/CarDN complex elute from column after overnight 
digestion with PreScission protease. Red circles mark CarDN and Taq RNAP β1m at 7 and 23 kDa respectively in 
lane 2. Lane 6: Beads after elution of the complex 
0
ft r incubating GS-bound CarD and Taq RNAP β1m for 3 h; Lane 10: GS beads after elution of
CarDN/Taq RNAP β1m. Red circles mark T q RNAP β1m and GST-CarDN fusion protein at 23 and 34 kDa
resp ctfully. B) Lane 1: Protein marker; Lanes 2 to 5: CarDN/Taq RNAP β1m complex was eluted from column
after overnig t cl avage with PreScission protease. Red circles mark CarDN and T q RNAP β1m at 7 and 23 kDa
respectively in lane 2. Lane 6: Beads after elution of the complex 
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4.0 Discussion 
4.1 Codon Usage and Gene Expression 
 
Of a total of 64 possible three-base codons, 61 code for amino acids, two for stop codons and 
one for N-terminal formyl-methionine. Depending on the organism, however, some codons 
for the same amino acid are used much more frequently (major codons) than others (rare 
codons) (Andersson & Sharp 1996). The usage frequency of individual codons correlates with 
the availability of the corresponding tRNA molecules. Heterologous expression of a gene may 
thus suffer from reduced efficiency due to previously major codons being rare in the 
expression host. Alternative outcomes include inhibition of protein synthesis, reduced cell 
growth, decreased mRNA stability, frame shifts and deletions (Berg & Silva 1997). In E. coli, 
normally no more than 10 rare codons per gene are tolerated (Andersson & Sharp 1996). 
The Mtb rnaP β1 gene contains only six codons considered rare in E. coli (Figure 3) implying 
that it should be produced. Nevertheless, despite successful cloning, Mtb RNAP β1 was not 
produced in E. coli BL 21+ after induction with IPTG. Reasons may include the very high GC-
content of Mtb rnaP β1. mRNA from GC-rich genes frequently form secondary structures 
(Berg & Silva 1997) resulting in low expression levels (Andersson & Sharp 1996; Berg & 
Silva 1997). This may partly explain the known difficulty in expressing genes of Mtb in E. 
coli. To overcome this limitation, genes may be codon harmonized by replacing guanines and 
cytosines near the 5’-end with adenines and thymines (Andersson & Sharp 1996). 
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4.2	Cloning	of	rnaP	β1	gene	
4.2.1 Restriction Free and conventional Cloning 
 
Restriction free (RF) cloning is a method allowing the insertion of a gene of interest at any 
desired location into a circular plasmid, independent of restriction sites, ligation or any 
modifications in both vector and gene (Ent & Löwe 2006; Ulrich et al. 2012). RF cloning is 
achieved in two independent PCR steps: in the first step the gene of interest is amplified using 
a set of plasmids, resulting in a linear product containing the target gene (fragment) flanked by 
5’ and 3’ regions complementary to the target plasmid. In the second PCR, the product of the 
first round anneals to the target plasmid by its flanking regions, resulting in the incorporation 
of the gene of interest into the expression plasmid after amplification. The advantage of RF 
cloning lies in facile primer design and a technical simplification compared to conventional 
cloning, which may suffer from incompatible restriction sites between expression plasmid and 
insert, as well as inefficiency of unbalanced restriction digestion. 
In this study, conventional and restriction free cloning methodologies were successfully 
combined after neither technique yielded the expected result on its own. The first phase of RF 
cloning allowed the amplification of Mtb rnaP β1 from genomic Mtb DNA. Conventional 
cloning was not successful in this step, possibly due to the high GC content of the Mtb 
genome, the large size of the genomic DNA, the shortness of the primers (Table 2) and the 
associated low efficiency of the annealing step. RF cloning primers by contrast are 
significantly longer (Table 2) allowing for higher annealing probabilities.  
In a second step, the linear DNA product of the first RF cloning step was successfully 
combined with primers for conventional cloning to generate a pre-restriction digest product 
for conventional ligation into an expression plasmid (Figure 8). Clearly, the gene of interest 
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was present in a significantly higher concentration as compared to genomic DNA, allowing 
for significantly more efficient annealing between primers and template DNA.  
Unexpectedly, the second phase of RF cloning was not successful. This may be due to the 
method’s inherent low efficiency for primers annealing to the vector for inserts of above 1000 
nucleotides (Ent & Löwe 2006).  
The overall successful cloning of rnaP β1 gene of Mtb was confirmed by Sanger sequencing. 
This serves to underscore that unconventional combinations of techniques may yield results 
where the methods individually did not. 
4.3 Site Directed Mutagenesis 
The success of site directed mutagenesis (SDM) depends on the length of region to mutate or 
delete (Ent & Löwe 2006). SDM was used successfully to generate CarDN from CarD by the 
insertion of a stop codon. The generation of CarDN by inserting a stop codon after the codon 
for the 64th amino acid was a relatively simple exercise as only 3 nucleotides needed to be 
inserted. 
However, SDM failed to replace the β1b domain of the successfully cloned Mtb rnaP β1 gene 
by a Gly-Gly linker to produce the conformationally stable Mtb RNAP β1m (see section 
4.2.1). This experiment entails replacing 600 nucleotides by a mere 6 in a gene of 1167 
nucleotides. This strategy has frequently been successful in the past inter alia for the 
equivalent experiment for Taq RNAP β1m (Westblade et al. 2010). The crystal structure of the 
complete Taq RNAP revealed the distance between the N- and C-termini of the inserted 
RNAP β1b to be 5.4 Å (Srivastava et al. 2013). Hence a GG-linker would be able to connect 
the two halves of the β1a subunit upon excision of β1b (Westblade et al. 2010).  
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The assumed CarD/RNAP protein-protein interaction area is located in the β1a subunit 
(Stallings et al. 2010). The successful cloning and production of Mtb RNAP β1m could have 
allowed the physiological complex with CarD to be studied in more detail as both proteins 
would derive from the same organism. Comparison of Taq and Mtb RNAP β1m (Figure 2) 
confirms that numerous exchanges of surface residues may result in Taq RNAP β1m being a 
poor substitute for Mtb RNAP β1m. 
An alternative strategy would have been to amplify the entire plasmid except the region to be 
deleted by employing primers that introduce a Gly and identical restriction sites to either end 
of the retained sequence. Using a single restriction enzyme and ligating the resulting 
circularized plasmid, the β1b domain could be removed – though depending on the restriction 
site, additional residues could potentially be introduced. 
4.4 Protein Production and Purification 
4.4.1 CarD and CarD N-terminal Domain 
 
Both CarD and CarDN were soluble when produced and expressed in BL21 E. coli cells as 
indicated in Figures 9 and 11. This correlates with the computational prediction of CarD 
solubility in PBS pH 7.4 buffer (Priya & Megha 2012). The same analysis predicted CarD to 
be stable in this buffer. Experimentally, this proved not to be the case as CarD significantly 
degraded within 2 days. Instead, 5 % (v/v) glycerol was found to be required to stabilize CarD 
for more than 67 days. Why glycerol should stabilize CarD is not entirely clear but an 
explanation could be that glycerol shields exposed hydrophobic surface patches in CarD 
(Bondos &Bicknell 2003) increasing its stability (Gekkot & Timasheff 1981) and 
compactness (Vagenende et al. 2009). At the same time, glycerol is a chaotrope and its 
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stabilizing effect is highly concentration dependent. Too much glycerol could (partly) unfold 
CarD while too little would not help to stabilize CarD (Gekkot & Timasheff 1981). 
A second purification step of CarD by anion exchange chromatography surprisingly led to its 
rapid degradation in less than 1 h (Figure10). The sudden destabilization of CarD led to the 
speculation that the selective removal of a cofactor such as an (oligo)nucleotide – shown to 
bind to the C-terminal domain of CarD (Garcı et al. 2010; Srivastava et al. 2013) – during 
anion exchange chromatography could be responsible. However, this interpretation had to be 
revisited when CarDN was similarly degraded after anion exchange chromatography, despite 
not being implicated in DNA or RNA binding. An alternative explanation could involve the 
effect of NaCl. Proteins purified by anion exchange chromatography are eluted at higher NaCl 
concentrations than the original buffer (section 2.4.2.3). For most proteins this would not be a 
problem, as “salting out” mostly only happens under very high salt conditions. CarD though 
may be more sensitive to a high ion concentration.  Yet a further explanation may involve the 
high ion concentration in the matrix of the ion exchange column. This could partially unfold 
inherently unstable CarD increasing its sensitivity to proteolytic cleavage (Gekkot & 
Timasheff 1981). 
CarDN did not require glycerol for stability, implying that the source of CarD instability 
involves the C–terminal domain. What is known about the C-terminal domain is that it binds 
DNA. However, the conclusion that nucleotides are critical to the stability of CarD may be 
premature.  
  
 
 
 
 
60 
 
4.4.2 Production of Mtb RNAP β1 versus that of Taq RNAP β1m 
While Taq rnaP β1m in plasmid pET28a produced soluble protein in E. coli BL21+ 
(Figure14), Mtb rnaP β1 in pGEX-6P-2 did not. A band observed in SDS-PAGE analysis (red 
arrow, Figure 13) roughly corresponded to the expected 70 kDa of the GST-Mtb RNAP β1 
fusion protein. The protein, however, did not bind to GS beads implying that it is not protein 
of interest. Of course Mtb proteins are notoriously difficult to produce in E. coli due to their 
high GC-content (section 4.1). Using the related Mycobacterium smegmatis, which has a 
similarly GC-rich genome, as expression host could provide a solution. Except that the 
replication time of M. smegmatis is 3 h (Noens et al. 2011), significantly extending the time 
required for protein production. 
4.4.3 CarD/RNAP Complex 
 Complex formation between Taq RNAP β1m and CarD was investigated by two related yet 
inverted pull-down assays involving both GST and Ni2+-NTA affinity chromatography to 
immobilize the bait. This technique is used extensively to confirm suspected interactions and 
to map interaction sites (Wysocka 2006). After coupling GST-CarD or GST-CarDN fusion 
protein to the GS matrix, Taq RNAP β1m was added and incubated. Unbound protein was 
eluted, the column rinsed, and the suspected complex eluted after proteolytic release of CarD. 
In the Ni2+-NTA pull-down, His6-tagged Taq RNAP β1m was coupled to Ni2+-NTA beads, 
CarD/CarDN added and incubated, unbound proteins removed and the suspected complex 
eluted with 250 mM imidazole. 
The results in Figures 17, 18 and 19 indicate that the GST pull-down proved superior to its 
Ni2+-NTA equivalent. It confirms the predicted complex between CarD and Taq RNAP β1m 
(Stallings et al. 2010; Srivastava et al. 2013; Weiss et al. 2012; Priya & Megha 2012; 
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Westblade et al. 2010). It also confirms that CarD interacts with Taq RNAP β1m through its 
N-terminal domain (Figure 20) as both CarD and CarDN successfully recruit Taq RNAP β1m. 
Despite experimental variations and imperfections, a stoichiometry of 1:1 best explains the 
observations. 
Reasons for the failure of the Ni2+-NTA pull-down assay, include the N-terminal His6-tag of 
Taq RNAP β1m which could sterically interfere with complex formation (Srivastava et al. 
2013). However, this is an unlikely explanation, as the His6-tag is similarly present in the 
successful GST pull-down experiments. Instead it seems more likely that the high imidazole 
concentration used to wash and elute the suspected complex could actually destabilize the 
inherently weak complex leading to the premature elution of CarD.  
While glycerol does stabilize CarD, it also has the disadvantage of increasing the buffer 
viscosity. This correspondingly slowed the proteolytic activity of PreScission protease 
dramatically reducing the cleavage of the GST-CarD fusion protein compared to GST-CarDN 
which did not require the addition of glycerol for stability (Figures 18  and 19).  
CarDN appears to be related to a family of RNAP-binding domains including the RNA 
interacting domain (RID) of transcription repair coupling factor (TRCF). The crystal structure 
of TRCF/Taq RNAP β1m (Priya & Megha 2012; Weiss et al. 2012) therefore provides a model 
of the interaction of these complexes. Isoleucine 108, glutamate 110 and lysine 109 of TRCF-
RID β1 are central to the interaction (Westblade et al. 2010). As these residues are conserved 
in CarD, they may be similarly critical to CarD/RNAP complex formation. A crystal structure 
of CarD/RNAP β1 could serve to confirm this analogy and could answer questions such as: 1) 
What is the role of the C-terminal domain of CarD? 2) What forces stabilize the complex? 3) 
Which residues are important in the interaction? 
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5.0 Conclusion/Outlook 
 
This work experimentally confirms the previously proposed interaction of CarD from Mtb 
through its N-terminal domain with Taq RNAP β1m. This complex is critical for Mtb to attain 
a state of dormancy that inter alia limits the efficacy of antibiotics in fighting this disease. The 
crystal structure of this complex has not yet been elucidated, which leaves a void in 
understanding the molecular basis of how CarD interacts and regulates RNAP. The C-terminal 
domain also needs to be investigated in more depth to identify its function in dormancy or in 
the interaction with RNAP. 
The CarD/RNAP complex provides an exciting avenue for TB therapeutic intervention. Small 
molecules could potentially be used to disrupt this complex forcing Mtb out of dormancy to 
restore its susceptibility to conventional antibiotics. The efficacy of this strategy is 
underscored by the mechanism of rifampicin, which inhibits transcription from the DNA 
dependent RNAP. This shows that the targeting of RNAP can be utilized in combating Mtb, 
highlighting the crucial importance of this complex.  
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